 | Up a level |
Gao, Qinglei and Zhu, Jianqing and Zhao, Weidong and Huang, Yi and An, Ruifang and Zheng, Hong and Qu, Pengpeng and Wang, Li and Zhou, Qi and Wang, Danbo and Lou, Ge and Wang, Jing and Wang, Ke and Low, John and Kong, Beihua and Abdul Malik, Rozita and Sen, Lim Chun and Yin, Rutie and Xie, Xing and Liu, Jihong and Sun, Wei and Su, Jingya and Zhang, Chunyi and Zang, Rongyu and Ma, Ding (2022) Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA). Clinical Cancer Research, 28 (11). pp. 2278-2285. ISSN 1078-0432, DOI https://doi.org/10.1158/1078-0432.CCR-21-3023.
Liam, Chong Kin and Ahmad, Azura Rozila and Hsia, Te-Chun and Zhou, Jianying and Kim, Dong-Wan and Soo, Ross Andrew and Cheng, Ying and Lu, Shun and Shin, Sang Won and Yang, James Chih-Hsin and Zhang, Yiping and Zhao, Jun and Berghoff, Karin and Bruns, Rolf and Johne, Andreas and Wu, Yi-Long (2023) Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research, 29 (10). pp. 1879-1886. ISSN 1078-0432, DOI https://doi.org/10.1158/1078-0432.CCR-22-3318.
